Clouds of care

What Clouds of care does

Clouds of Care (legal entity: Clouds of Care N.V.) is a Ghent, Belgium-based clinical development services and medical device company founded in 2016 as a spin-off from Ghent University, Antwerp University, and Imec. The company specializes in applying electrophysiology — EEG, event-related potentials (ERP), and polysomnography (PSG) — to improve the detection and interpretation of treatment effects in central nervous system (CNS) clinical trials. Its core offering is the CNS Platform, a vendor-neutral, AI-powered system that combines proprietary biomarker algorithms (including Persyst ESI powered by Epilog, an FDA-cleared and CE-marked Class IIa medical device for automated EEG source imaging) with a curated network of digital health technology partners for data acquisition, aggregation, and analysis across epilepsy, developmental and epileptic encephalopathies (DEEs), neurodegeneration (Alzheimer's and Parkinson's), and sleep disorders.

The company's revenue is generated through bespoke enterprise contracts with biotech, pharma, and MedTech sponsors running CNS trials, delivered via direct field sales supported by conference-driven thought leadership. Service offerings span multimodal endpoint advisory, DHT partner selection, EEG/ERP/PSG data acquisition and analysis, standardized pharmaco-EEG (following IPEG guidelines), endpoint validation, and interpretation and result reporting. A secondary revenue stream comes from medical device licensing through the Persyst platform for clinical epilepsy centers. The company reports it has enriched over 20 CNS clinical trials across 8 years of operation, with named customers including Biohaven, UCB, Neurocrine, Ionis, Longboard Pharmaceuticals, Stoke Therapeutics, GRIN Therapeutics, and ECET, as well as hospital implementations at Yale New Haven Hospital and Kuopio University Hospital.

Clouds of Care has raised a cumulative €7M in disclosed funding (€1M seed in June 2021, €5M Series A in September 2024 led by TCD Capital with FFTF and White Fund, and a €2M extension in June 2025 joined by Novalis Biotech Acceleration Fund). The leadership team is anchored by founders Gregor Strobbe (CEO) and Pieter Van Mierlo (CSO), with former Biogen CEO Michel Vounatsos serving as Chairman. The company holds ISO 13485:2016 and ISO 27001:2013 certifications, is GDPR compliant, and operates from a single headquarters in Ghent with a historical US office presence channeled through Persyst Development LLC (Solana Beach, CA).

Name

Clouds of care

Legal name

Clouds of Care N.V.

Website

https://cloudsofcare.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Clouds of Care provides AI-powered electrophysiology biomarker services and a vendor-neutral CNS clinical trial platform, enabling biotech, pharma, and MedTech sponsors to integrate EEG, ERP, and PSG endpoints into drug development across epilepsy, neurodegeneration, and rare CNS disorders.

Ownership category

akta.pro rank

Product category

CNS Clinical Trial Services

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (541690)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

Keywords

• CNS clinical trials
• EEG biomarker services
• Electrophysiology analysis
• Neurological diagnostics
• Clinical development services

Headquarters

HQ city

Ghent

HQ country

Belgium

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical development services: Bespoke CNS clinical development services for Biotech, Pharma, and MedTech companies, including multimodal endpoint advisory, DHT partner selection, data acquisition and analysis, endpoint validation, and interpretation and result reporting.
2. Medical device licensing (Persyst ESI powered by Epilog): CE-marked and FDA-cleared medical device (Class IIa) offered as a service to hospitals and clinical centers for automated EEG source imaging in refractory epilepsy evaluation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Clouds of Care provides EEG-based biomarker services and bespoke clinical development services for CNS (central nervous system) clinical trials. The company combines electrophysiology (EEG, ERP, PSG) with a multimodal AI-powered biomarker platform to deliver objective neurophysiological endpoints, DHT partner selection, data acquisition and analysis, and endpoint validation. Their flagship medical device, Persyst ESI powered by Epilog, is an FDA-cleared and CE-marked Class IIa software device for automated electrical source imaging in epilepsy presurgical evaluation.

Product overview

Clouds of Care offers a unified CNS clinical development platform built around multimodal AI-powered biomarker services. The core offering consists of the CNS Platform—a vendor-neutral, integrated system connecting curated digital health technology partners for data collection, aggregation, and analysis. Key products include Persyst ESI powered by Epilog (FDA-cleared/CE-marked electrical source imaging), Epilog PreOp (automated EEG analysis for presurgical evaluation), and Sleep Insights (PSG analysis). Clinical Development Services provide end-to-end support including multimodal endpoints advisory, DHT partner selection, and interpretation/reporting. The platform is complemented by specialized services like Pharmaco-EEG and ERP Assessments for rare pediatric conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Persyst ESI powered by Epilog: FDA-cleared and CE-marked Software as a Medical Device (SaMD) for electrical source imaging, used for localization of epileptogenic zone in refractory epilepsy.

Products and services

• CNS Platform Vendor-neutral, integrated cloud platform that connects best-matched acquisition hardware and analysis software, harmonizing data collection, aggregation, and analysis to enable multimodal insights in CNS clinical development.
• Persyst ESI powered by Epilog FDA-cleared and CE-marked Class IIa software as a medical device (SaMD) for automated electrical source imaging that estimates underlying brain activity from EEG using electromagnetic models built from patient MRI, used to localize the epileptogenic zone in refractory epilepsy evaluation.
• Epilog PreOp FDA-cleared automated EEG analysis service for long-term EEG diagnostics and source localization during preoperative evaluation in epilepsy.
• Epilog Diagnostic Automated analysis service for overnight or 24-hour EEG recordings providing concise diagnostic reports within 24 hours with 83% sensitivity and 94% specificity for epilepsy diagnosis.
• Sleep Insights (Somnilog) Polysomnography (PSG) analysis solution for sleep disorders assessment, integrated into the CNS platform.
• Clinical Development Services Bespoke service offering including multimodal endpoints advisory, DHT partner selection, data acquisition/aggregation/analysis, endpoint validation, and interpretation/reporting for CNS clinical trials.
• Pharmaco-EEG Services Standardized pharmaco-EEG services measuring pharmacodynamic and pharmacokinetic properties of CNS-active compounds, following IPEG guidelines, including expert consulting, study preparation, data handling, and reporting.
• ERP Assessments Event-related potential assessments using scalp EEG to evaluate cognitive and socio-emotional development in pre-verbal or minimally communicative pediatric patients, leveraging endpoints such as P300, MMN, ABR, N170, and ERN.

Quantifiable outcome

• Persyst ESI powered by Epilog achieved 80% sensitivity and 75% specificity in localizing the epileptogenic zone in a validation study of 32 patients (Epilepsia Open, 2017).
• +3 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability6 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Persyst Development LLCcoreTechnology or Integration · 1 December 2019Partnership agreement signed December 2019 with Persyst, the global leader in EEG software. The partnership enabled Epilog to scale commercialization of its EEG source imaging product (PreOp/ESI) through Persyst's platform. Persyst ESI powered by Epilog is integrated into Persyst's EEG Review and Analysis Software and is compatible with all major EEG hardware vendors. Persyst Development LLC (420 Stevens Avenue, Suite 210, Solana Beach, CA 92075) offers the clinical service to healthcare professionals.
• ANT NeurosupportingTechnology or IntegrationEEG hardware partner for ERP assessments in rare pediatric CNS disorders. ANT Neuro provides fit-for-purpose EEG equipment for developmentally and age-appropriate acquisition protocols in pediatric clinical trials.
• IndivicoreStrategic or Co-development PartnerPartnership with Indivi (Basel-based TechBio company) for the development and validation of EEG biomarkers for Alzheimer's disease clinical trials. Indivi's expertise in treatment response biomarkers combined with Clouds of Care's multimodal EEG platform for early detection of pharmacodynamic response in neurodegenerative disease.
• NeurotechsupportingTechnology or IntegrationEEG hardware specialist partner providing equipment for at-home EEG data collection in rare pediatric epilepsy natural history studies, enabling multi-day wearable EEG acquisition.
• DeltaclinicalsupportingTechnology or IntegrationClinical trial support partner providing services for at-home EEG data collection across multiple countries in rare pediatric epilepsy studies, ensuring consistent procedures and standardized training of EEG technicians.
• BytefliessupportingTechnology or IntegrationWearable EEG technology partner contributing to at-home EEG monitoring solutions in rare pediatric epilepsy studies, enabling continuous multi-day data acquisition in the patient's natural environment.
• Digital Medicine Society (DiMe) - DATAcc projectsupportingStrategic or Co-development PartnerClouds of Care joined DiMe's DATAcc project team to develop a core set of digital measures for pediatric rare diseases, collaborating with industry leaders across pharma, biotech, MedTech, regulatory bodies, and patient advocacy groups to advance digital endpoints for children with rare diseases.
• Curated DHT Partners (CNS Platform ecosystem)coreTechnology or IntegrationCNS Platform features a curated network of DHT partners providing best-matched acquisition hardware and analysis software for CNS clinical trials. Partners include EEG specialists, sleep monitoring companies, wearable device providers, and digital health technology firms, all integrated through a single platform for multimodal data solutions.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Beacon Biosignals: US-based AI-focused EEG biomarker company providing quantitative EEG analysis and endpoint solutions for CNS clinical trials across epilepsy, sleep, and neurodegeneration. Closely comparable in business model (specialized EEG biomarker services for pharma trial sponsors) and target customers.
• Cumulus Neuroscience: Provides a multimodal platform combining EEG, cognitive testing, and digital biomarkers for CNS clinical trials, primarily in neurodegeneration. Directly comparable target market (CNS trial sponsors) and overlapping technology approach (multimodal electrophysiology + DHT).
• Persyst Development Corporation: Global leader in EEG review and analysis software and Clouds of Care's primary distribution partner. Comparable core technology (EEG analysis) and overlapping customers (epilepsy centers and pharma); partnership and competitive dynamic simultaneously.
• IXICO: UK-based neuroimaging biomarker CRO providing MRI and PET analytics for CNS clinical trials, including neurodegeneration. Comparable business model (specialist CNS clinical trial analytics services for pharma/biotech sponsors) with adjacent (imaging) rather than identical (EEG) modality.
• Wave Neuroscience: EEG-based diagnostic and treatment company with presence in clinical research. Comparable core technology (quantitative EEG) and adjacent positioning in CNS applications; smaller and earlier-stage than Clouds of Care.
• iMediSync: Korea-based AI EEG diagnostic and biomarker company developing cloud-based EEG analytics for early detection of neurological disorders including Alzheimer's. Comparable core technology (AI EEG biomarkers) and target indication overlap (neurodegeneration).

Broad incumbents

• Ceribell: US-based commercial-stage medtech offering AI-powered continuous EEG monitoring for hospital inpatients (acute care). Overlaps on EEG AI core technology but serves an entirely different customer segment (hospitals for critical care) and is a much larger, public company.
• Clario: Major clinical trial technology company formed via the merger of ERT and Bioclinica, offering a broad portfolio of eCOA, imaging, cardiac safety, and respiratory endpoints including EEG capabilities. Broader and larger competitor with multi-modality endpoint bundling for pharma trials.

Emerging players

• Cambridge Cognition: AIM-listed provider of cognitive assessment technology and digital endpoints for CNS clinical trials. Comparable business model (CNS trial endpoints for pharma) with complementary (cognitive testing) rather than overlapping (EEG) modality.
• Cogstate: Public digital health company providing computerized cognitive testing and eCOA for CNS clinical trials across neurodegeneration, psychiatry, and rare disease. Comparable customers and endpoint positioning in CNS trials with an adjacent (cognitive) modality focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cloudsofcare

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clouds of care